Exscientia Ltd ADR (EXAI) Stock
EXAI is no longer traded. Exscientia Ltd ADR was delisted from the Nasdaq in November 2024.
Prices on this page are historical; the last trade was November 19, 2024 at $4.84.
Exscientia Ltd ADR stock price history
EXAI final trading statistics
- Final close
- $4.84
- Final trading day
- Nov 19, 2024
- Market cap at delisting
- $633.18M
- Shares outstanding
- 130.82M
- Final 52-week range
- $3.80 – $7.91
- Avg. volume (final 3 mo.)
- 716,453
- All-time high (split-adj.)
- $27.10 · Oct 2021
- All-time low (split-adj.)
- $3.99 · Apr 2024
- Return since IPO
- -82.1%
- Beta
- 0.83
- Book value / share
- $1.95
- Price / book
- 2.48
Exscientia Ltd ADR annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $20.08M | -$146.0M | -$1.49 |
| FY2022 | $26.82M | -$116.7M | -$1.40 |
| FY2021 | $20.32M | -$36.5M | -$1.16 |
| FY2020 | $13.18M | -$30.4M | -$0.22 |
| FY2019 | $11.94M | -$8.3M | -$0.04 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Exscientia Ltd ADR
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité " Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.
Exscientia Ltd ADR stock FAQ
What happened to Exscientia Ltd ADR stock?
Exscientia Ltd ADR stock was delisted from the Nasdaq. Its final close was $4.84 on November 19, 2024.
Is EXAI stock still trading?
No. EXAI was delisted from the Nasdaq in November 2024 and no longer trades on a U.S. exchange.
What was the last price of EXAI stock?
EXAI closed at $4.84 on its final trading day, November 19, 2024, for a market value of about $633.18M.
What were Exscientia Ltd ADR's revenue and earnings in its last full fiscal year?
Exscientia Ltd ADR reported revenue of $20.08M and net income of -$146.0M in fiscal 2023, its last full year as a public company.
When did Exscientia Ltd ADR go public?
Exscientia Ltd ADR stock began trading on October 1, 2021.